16 results on '"Ruiz JM"'
Search Results
2. [Ophthalmic manifestations in patients recovered from COVID-19 in Mexico].
- Author
-
Hernández-Reyes FJ, Garza-Arreola Á, Muñoz-Pérez A, Martínez-Mier G, Jiménez-López LA, Bernal-Dolores V, and Reyes-Ruiz JM
- Abstract
Introduction and Objectives: Although the ophthalmic manifestations appear to be associated with the coronavirus disease 2019 (COVID-19), there is not enough evidence. Hence, the aim of this study was to determine the various types and frequency of ophthalmic manifestations in patients recovered from SARS-CoV-2 infection in Mexico., Material and Methods: This retrospective, observational and descriptive study included all patients recovered from SARS-CoV-2 infection attending the tertiary level hospital of Mexican Social Security Institute (IMSS) from June 2020 to June 2022. During the hospital admission of patients, the demographic data such age, name, gender was recorded. Ophthalmologic examination was performed under torchlight by an ophthalmologist in the Department of Ophthalmology from IMSS. Data was compiled and statistically analyzed using Fisher's exact test and Spearman correlation., Results: A total of 3,081 SARS-CoV-2-positive patients were recorded, of which 318 (10.32%) met the inclusion criteria. Of them, 21 (6.60%) had ophthalmic manifestations and the female-to-male ratio was 1.6:1. The mean age (±SD) was 47.95 ± 15.27 years and the median (interquartile range) time from the diagnosis of COVID-19, as defined by positive SARS-CoV-2 RT-PCR testing, to detection of the ophthalmic manifestation was 31 (142) days. The most common ocular manifestation was orbital mucormycosis (23.80%). Interestingly, the presence of ophthalmic manifestations was not associated with severe COVID-19 ( p = 0.665)., Conclusions: The ophthalmic manifestations are infrequent in patients recovered from severe COVID-19. Nevertheless, further large sample studies are needed to confirm these findings., (© 2023 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
3. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology.
- Author
-
Narváez J, Aburto M, Seoane-Mato D, Bonilla G, Acosta O, Candelas G, Cano-Jiménez E, Castellví I, González-Ruiz JM, Corominas H, López-Muñiz B, Martín-López M, Robles-Pérez A, Mena-Vázquez N, Rodríguez-Portal JA, Ortiz AM, Sabater-Abad C, Castrejón I, Dos Santos R, Garrote-Corral S, Maese J, Silva-Fernández L, Castañeda S, and Valenzuela C
- Subjects
- Humans, Rheumatologists, Risk Factors, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid diagnosis, Lung Diseases, Interstitial complications, Lung Diseases, Interstitial diagnosis, Rheumatology
- Abstract
Objective: To develop a joint proposal for screening criteria of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) and vice versa, which serves as a guidelines in patient referral between the Rheumatology and Pneumology departments to early detection of these patients., Methods: A systematic literature review was carried out on the risk factors for the development of ILD in RA patients, and for the referral criteria to Rheumatology for suspected early RA. Based on the available evidence, screening criteria were agreed using the Delphi method by a panel of pneumologists and rheumatologists with expertise in these pathologies., Results: Screening criteria for ILD in patients with RA and for the early detection of RA in cases with ILD of unknown etiology have been developed. In both cases, a detection strategy was based on clinical risk factors. Recommendations also included the complementary tests to be carried out in the different clinical scenarios and on the periodicity that screening should be repeated., Conclusion: A selective screening strategy is recommended for the first time in the early diagnosis of patients with ILD-RA. This multidisciplinary proposal aims to solve some common clinical questions and help decision-making, although its usefulness to identify these patients with good sensitivity must be confirmed in a validation study., (Copyright © 2022. Published by Elsevier España, S.L.U.)
- Published
- 2023
- Full Text
- View/download PDF
4. Preventing ventricular arrhythmias and sudden cardiac death in adults with repaired tetralogy of Fallot: a never-ending story?
- Author
-
Oliver-Ruiz JM and Peinado-Peinado R
- Subjects
- Adult, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac etiology, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac prevention & control, Humans, Tetralogy of Fallot surgery
- Published
- 2021
- Full Text
- View/download PDF
5. Coexistence of transmural and lateral wavefront progression of myocardial infarction in the human heart.
- Author
-
Lorca R, Jiménez-Blanco M, García-Ruiz JM, Pizarro G, Fernández-Jiménez R, García-Álvarez A, Fernández-Friera L, Lobo-González M, Fuster V, Rossello X, and Ibáñez B
- Subjects
- Contrast Media, Gadolinium, Humans, Metoprolol therapeutic use, Myocardial Infarction complications, Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction complications, ST Elevation Myocardial Infarction diagnosis
- Abstract
Introduction and Objectives: According to the wavefront phenomenon described in the late 1970s, myocardial infarction triggered by acute coronary occlusion progresses with increasing duration of ischemia as a transmural wavefront from the subendocardium toward the subepicardium. However, whether wavefront progression of necrosis also occurs laterally has been disputed. We aimed to assess the transmural and lateral spread of myocardial damage after acute myocardial infarction in humans and to evaluate the impact of metoprolol on these., Methods: We assessed myocardial infarction in the transmural and lateral dimensions in a cohort of 220 acute ST-segment elevation myocardial infarction (STEMI) patients from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). The patients underwent cardiac magnetic resonance imaging at 5 to 7 days and 6 months post-STEMI., Results: On day 5 to 7 post-STEMI cardiac magnetic resonance, there was a strong linear correlation between the transmural and lateral extent of infarction (delayed gadolinium enhancement) (r=-0.88; P<.001). Six months after STEMI, myocardial scarring (delayed gadolinium enhancement) was significantly less extensive in the transmural and lateral dimensions, suggesting that infarct resorption occurs in both. Furthermore, progression in both directions occurred both in patients receiving metoprolol and control patients, implying that myocardial salvage occurs both in the transmural and the lateral direction., Conclusions: Our findings challenge the assumption that irreversible injury does not spread laterally. A "circumferential" or multidirectional wavefront would imply that cardioprotective therapies might produce meaningful salvage at lateral borders of the infarct. This trial was registered at ClinicalTrial.gov (Identifier: NCT01311700)., (Copyright © 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
6. The use of Bayes factor in clinical cardiology research. Response.
- Author
-
Monteagudo Ruiz JM, Solano-López J, Zamorano JL, and Sánchez-Recalde Á
- Subjects
- Bayes Theorem, Humans, Cardiology, Research Design
- Published
- 2021
- Full Text
- View/download PDF
7. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry.
- Author
-
Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, González-Costello J, López-Fernández S, García-Pinilla JM, Almenar-Bonet L, de Juan-Bagudá J, Roig-Minguell E, Bayés-Genís A, Sanz-Julve M, Lambert-Rodríguez JL, Lara-Padrón A, Pérez-Ruiz JM, Fernández-Vivancos Marquina C, de la Fuente-Galán L, Varela-Román A, Torres-Calvo F, Andrés-Novales J, Escudero-González A, Pascual-Figal DA, Ridocci-Soriano F, Sahuquillo-Martínez A, Bierge-Valero D, Epelde-Gonzalo F, Gallego-Page JC, Dalmau González-Gallarza R, Bover-Freire R, Quiles-Granado J, Maggioni AP, Lund LH, Muñiz J, and Delgado-Jiménez J
- Subjects
- Aged, Aged, 80 and over, Female, Heart Failure complications, Heart Failure physiopathology, Humans, Hyperkalemia blood, Hyperkalemia epidemiology, Incidence, Male, Middle Aged, Mineralocorticoid Receptor Antagonists therapeutic use, Risk Factors, Spain epidemiology, Treatment Outcome, Guideline Adherence, Heart Failure drug therapy, Hyperkalemia etiology, Potassium blood, Registries, Spironolactone therapeutic use, Stroke Volume physiology
- Abstract
Introduction and Objectives: Hyperkalemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction because it limits the use of effective drugs. We report estimates of the magnitude of this problem in routine clinical practice in Spain, as well as changes in potassium levels during follow-up and associated factors., Methods: This study included patients with acute (n=881) or chronic (n=3587) heart failure recruited in 28 Spanish hospitals of the European heart failure registry of the European Society of Cardiology and followed up for 1 year. Various outcomes were analyzed, including changes in serum potassium levels and their impact on treatment., Results: Hyperkalemia (K
+ > 5.4 mEq/L) was identified in 4.3% (95%CI, 3.7%-5.0%) and 8.2% (6.5%-10.2%) of patients with chronic and acute heart failure, respectively, and was responsible for 28.9% of all cases of contraindication to mineralocorticoid receptor antagonist use and for 10.8% of all cases of failure to reach the target dose. Serum potassium levels were not recorded in 291 (10.8%) of the 2693 chronic heart failure patients with reduced ejection fraction. During follow-up, potassium levels increased in 179 of 1431 patients (12.5%, 95%CI, 10.8%-14.3%). This increase was directly related to age, diabetes, and history of stroke and was inversely related to history of hyperkalemia., Conclusions: This study highlights the magnitude of the problem of hyperkalemia in patients with heart failure in everyday clinical practice and the need to improve monitoring of this factor in these patients due to its interference with the possibility of receiving optimal treatment., (Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
8. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
- Author
-
Raposeiras-Roubín S, Abu-Assi E, Cespón-Fernández M, Ibáñez B, García-Ruiz JM, D'Ascenzo F, Simao Henriques JP, Saucedo J, Caneiro-Queija B, Cobas-Paz R, Muñoz-Pousa I, Wilton SB, González Juanatey JR, Kikkert WJ, Núñez-Gil I, Ariza-Solé A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Gaita F, Huczek Z, Nie SP, Yan Y, Fujii T, Correia L, Kawashiri MA, Kedev S, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Möllmann H, Shiomi H, Giordana F, Kowara M, Filipiak K, Wang X, Fan JY, Ikari Y, Nakahayshi T, Sakata K, Yamagishi M, Kalpak O, and Íñiguez-Romo A
- Subjects
- Acute Coronary Syndrome mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Propensity Score, Registries, Retrospective Studies, Treatment Outcome, Acute Coronary Syndrome therapy, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Percutaneous Coronary Intervention methods, Renin-Angiotensin System drug effects, Stroke Volume physiology, Ventricular Function, Left physiology
- Abstract
Introduction and Objectives: For patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), it is unclear whether angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are associated with reduced mortality, particularly with preserved left ventricular ejection fraction (LVEF). The goal of this study was to determine the association between ACEI/ARB and mortality in ACS patients undergoing PCI, with and without reduced LVEF., Methods: Data from the BleeMACS registry were used. The endpoint was 1-year all-cause mortality. The prognostic value of ACEI/ARB was tested after weighting by survival-time inverse probability and after adjustment by Cox regression, propensity score, and instrumental variable analysis., Results: Among 15 401 ACS patients who underwent PCI, ACEI/ARB were prescribed in 75.2%. There were 569 deaths (3.7%) during the first year after hospital discharge. After multivariable adjustment, ACEI/ARB were associated with lower 1-year mortality, ≤ 40% (HR, 0.62; 95%CI, 0.43-0.90; P=.012). The relative risk reduction of ACEI/ARB in mortality was 46.1% in patients with LVEF ≤ 40%, and 15.7% in patients with LVEF> 40% (P value for treatment-by-LVEF interaction=.008). For patients with LVEF> 40%, ACEI/ARB was associated with lower mortality only in ST-segment elevation myocardial infarction (HR, 0.44; 95%CI, 0.21-0.93; P=.031)., Conclusion: The benefit of ACEI/ARB in decreasing mortality after an ACS in patients undergoing PCI is concentrated in patients with LVEF ≤ 40%, and in those with LVEF> 40% and ST-segment elevation myocardial infarction. In non-ST-segment elevation-ACS patients with LVEF> 40%, further studies are needed to assess the prognostic impact of ACEI/ARB., (Copyright © 2019. Published by Elsevier España, S.L.U.)
- Published
- 2020
- Full Text
- View/download PDF
9. Importance of the Left Ventricle in Secondary Mitral Regurgitation. Hunt With Cats and You Catch Only Rats.
- Author
-
Monteagudo Ruiz JM and Zamorano Gómez JL
- Subjects
- Echocardiography, Heart Valve Prosthesis Implantation methods, Heart Ventricles physiopathology, Humans, Mitral Valve surgery, Mitral Valve Insufficiency physiopathology, Mitral Valve Insufficiency surgery, Heart Ventricles diagnostic imaging, Mitral Valve diagnostic imaging, Mitral Valve Insufficiency diagnosis, Stroke Volume physiology, Ventricular Function, Left physiology
- Published
- 2019
- Full Text
- View/download PDF
10. Prevalence of Neuroendocrine Tumors in Patients With Cyanotic Congenital Heart Disease.
- Author
-
Ponz de Antonio I, Ruiz Cantador J, González García AE, Oliver Ruiz JM, Sánchez-Recalde Á, and López-Sendón JL
- Subjects
- Adult, Comorbidity trends, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prevalence, Retrospective Studies, Spain epidemiology, Young Adult, Forecasting, Heart Defects, Congenital epidemiology, Neuroendocrine Tumors epidemiology
- Published
- 2017
- Full Text
- View/download PDF
11. Accuracy of Area at Risk Quantification by Cardiac Magnetic Resonance According to the Myocardial Infarction Territory.
- Author
-
Fernández-Friera L, García-Ruiz JM, García-Álvarez A, Fernández-Jiménez R, Sánchez-González J, Rossello X, Gómez-Talavera S, López-Martín GJ, Pizarro G, Fuster V, and Ibáñez B
- Subjects
- Animals, Disease Models, Animal, Male, Predictive Value of Tests, Risk Assessment, Swine, Time Factors, Magnetic Resonance Imaging, Myocardial Infarction diagnostic imaging
- Abstract
Introduction and Objectives: Area at risk (AAR) quantification is important to evaluate the efficacy of cardioprotective therapies. However, postinfarction AAR assessment could be influenced by the infarcted coronary territory. Our aim was to determine the accuracy of T
2 -weighted short tau triple-inversion recovery (T2 W-STIR) cardiac magnetic resonance (CMR) imaging for accurate AAR quantification in anterior, lateral, and inferior myocardial infarctions., Methods: Acute reperfused myocardial infarction was experimentally induced in 12 pigs, with 40-minute occlusion of the left anterior descending (n = 4), left circumflex (n = 4), and right coronary arteries (n = 4). Perfusion CMR was performed during selective intracoronary gadolinium injection at the coronary occlusion site (in vivo criterion standard) and, additionally, a 7-day CMR, including T2 W-STIR sequences, was performed. Finally, all animals were sacrificed and underwent postmortem Evans blue staining (classic criterion standard)., Results: The concordance between the CMR-based criterion standard and T2 W-STIR to quantify AAR was high for anterior and inferior infarctions (r = 0.73; P = .001; mean error = 0.50%; limits = -12.68%-13.68% and r = 0.87; P = .001; mean error = -1.5%; limits = -8.0%-5.8%, respectively). Conversely, the correlation for the circumflex territories was poor (r = 0.21, P = .37), showing a higher mean error and wider limits of agreement. A strong correlation between pathology and the CMR-based criterion standard was observed (r = 0.84, P < .001; mean error = 0.91%; limits = -7.55%-9.37%)., Conclusions: T2 W-STIR CMR sequences are accurate to determine the AAR for anterior and inferior infarctions; however, their accuracy for lateral infarctions is poor. These findings may have important implications for the design and interpretation of clinical trials evaluating the effectiveness of cardioprotective therapies., (Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
12. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
- Author
-
Torrente-Segarra V, Acosta Pereira A, Morla R, Ruiz JM, Clavaguera T, Figuls R, Corominas H, Geli C, Roselló R, de Agustín JJ, Alegre C, Pérez C, García A, and Rodríguez de la Serna A
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Adalimumab therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Etanercept therapeutic use, Infliximab therapeutic use, Rituximab therapeutic use
- Abstract
Objective: to compare the short-term efficacy and safety of rituximab (RTX) therapy versus anti-TNF in rheumatoid arthritis (RA) patients after discontinuation of a first anti-TNF agent., Methods: prospective observational multicenter study in the clinical practice setting, involving patients with severe RA refractory to a first anti-TNF agent, who received either RTX or a second anti-TNF (2TNF), comparing the efficacy endpoints, EULAR response (Good/Moderate) and safety at 6 months., Results: 103 patients enrolled, 82 completed 6-month follow-up, 73.7% women. Baseline data for RTX and 2TNF groups, respectively: TJC, 8.6 and 6.6; SJC, 8.8 and 7.5; DAS28 score, 5.45 (±1.28) and 5.18 (±1.21) (p=0.048), ESR, 41 and 38.7mmHg; and HAQ, 1.2 and 1.0. Improvement was observed in all parameters, with no significant differences (except for a more marked reduction in ESR with RTX). There were no serious adverse events., Conclusions: RTX use as second-line therapy after anti-TNF failure led to improvements in the efficacy and functional variables at 6 months, with no serious adverse events. These results were comparable to those observed in patients who used a second anti-TNF agent in the same clinical scenario., (Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
13. Diabetes and Screening for Coronary Heart Disease: Where Should We Focus our Efforts?
- Author
-
de la Hera JM, García-Ruiz JM, and Delgado E
- Subjects
- Global Health, Humans, Prevalence, Coronary Artery Disease epidemiology, Diabetes Mellitus epidemiology, Mass Screening methods
- Published
- 2015
- Full Text
- View/download PDF
14. Time since diabetes onset as a determining factor in platelet reactivity.
- Author
-
de la Hera Galarza JM, García-Ruiz JM, Delgado Alvarez E, and Ferreiro JL
- Subjects
- Female, Humans, Male, Acute Coronary Syndrome blood, Acute Coronary Syndrome drug therapy, Blood Platelets drug effects, Hyperglycemia blood, Hyperglycemia drug therapy, Hypoglycemic Agents therapeutic use, Insulin therapeutic use
- Published
- 2014
- Full Text
- View/download PDF
15. Oral glucose tolerance test as a tool for patient improvement after percutaneous coronary intervention.
- Author
-
de la Hera JM, Delgado E, Martínez-Camblor P, Vegas JM, García-Ruiz JM, and Rodriguez-Lambert JL
- Subjects
- Follow-Up Studies, Humans, Kaplan-Meier Estimate, Recovery of Function, Secondary Prevention, Survival Analysis, Glucose Tolerance Test, Percutaneous Coronary Intervention
- Published
- 2012
- Full Text
- View/download PDF
16. Metabolic syndrome, diabetes, and coronary artery disease: a very common association.
- Author
-
Vegas-Valle JM, García-Ruiz JM, Hernández-Martín E, and de la Hera JM
- Subjects
- Female, Humans, Male, Acute Coronary Syndrome epidemiology, Metabolic Syndrome epidemiology
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.